CSIMarket
 


Atara Biotherapeutics Inc   (ATRA)
Other Ticker:  
 

Atara Biotherapeutics Inc 's Working Capital Ratio

ATRA's quarterly Working Capital Ratio and Current Assets, Current Liabilities growth


In the wake of the increase in Current Liabilities in the third quarter 2023, Working Capital Ratio fell to 1.5 a new company low.

Within Biotechnology & Pharmaceuticals industry 27 other companies have achieved higher Working Capital Ratio than Atara Biotherapeutics Inc in third quarter 2023. While Working Capital Ratio total ranking has improved so far during the III Quarter 2023 to 869, from total ranking in the second quarter 2023 at 1461.

Explain Working Capital Ratio
How much in Current Assets ATRA´s has?
What is the value of ATRA´s Current Liabilities?


ATRA Working Capital Ratio (Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Current Liabilities Change 9.47 % 13.49 % -33.17 % -25.4 % -16.14 %
Y / Y Current Assets Change -58.06 % -50.34 % -28.69 % -23.28 % -23.4 %
Working Capital Ratio MRQ 1.5 2.31 3.3 3.74 3.92
ATRA's Total Ranking # 869 # 1461 # 1237 # 1238 # 1407
Seq. Current Liabilities Change 6.09 % 9.84 % -13.99 % 9.24 % 9.98 %
Seq. Current Assets Change -31.12 % -23.13 % -24.03 % 4.25 % -18.43 %



Working Capital Ratio third quarter 2023 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 28
Healthcare Sector # 173
Overall Market # 869


Working Capital Ratio Statistics
High Average Low
52.75 16.35 1.5
(Sep 30 2015)   (Sep 30 2023)




Financial Statements
Atara Biotherapeutics Inc 's Current Liabilities $ 79 Millions Visit ATRA's Balance sheet
Atara Biotherapeutics Inc 's Current Assets $ 119 Millions Visit ATRA's Balance sheet
Source of ATRA's Sales Visit ATRA's Sales by Geography


Cumulative Atara Biotherapeutics Inc 's Working Capital Ratio

ATRA's Working Capital Ratio for the trailling 12 Months

ATRA Working Capital Ratio

(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Current Liabilities TTM Growth 9.47 % 13.49 % -33.17 % -25.4 % -16.14 %
Y / Y Current Assets TTM Growth -58.06 % -50.34 % -28.69 % -23.28 % -23.4 %
Working Capital Ratio TTM 2.7 3.32 4.04 3.89 3.85
Total Ranking TTM # 2257 # 4050 # 3191 # 3753 # 1129
Seq. Current Liabilities TTM Growth 6.09 % 9.84 % -13.99 % 9.24 % 9.98 %
Seq. Current Assets TTM Growth -31.12 % -23.13 % -24.03 % 4.25 % -18.43 %


On the trailing twelve months basis Due to rise in Current Liabilities in the III Quarter 2023 to $79.09 millions, cumulative Working Capital Ratio decreased to 2.7 below the Atara Biotherapeutics Inc average Working Capital Ratio.
Working Capital Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 135 other companies have achieved higher Working Capital Ratio than Atara Biotherapeutics Inc . While Working Capital Ratio overall ranking has improved so far to 2257, from total ranking during the twelve months ending second quarter 2023 at 4050.

Explain Working Capital Ratio
How much in Current Assets ATRA´s has?
What is the value of ATRA´s Current Liabilities?

TTM Working Capital Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 136
Healthcare Sector # 778
Within the Market # 2257


trailing twelve months Working Capital Ratio Statistics
High Average Low
23.46 8.95 2.7
(Jun 30 2017)   (Sep 30 2023)




Companies with similar Working Capital Ratio in the quarter ending Sep 30 2023, within Biotechnology & Pharmaceuticals Industry Working Capital RatioSep 30 2023 MRQ Current AssetsSep 30 2023 MRQ Current Liabilities
Alector Inc   3.95 $ 613.147  Millions$ 155.402  Millions
Gritstone Bio Inc   3.88 $ 90.820  Millions$ 23.383  Millions
Exelixis Inc   3.83 $ 1,443.369  Millions$ 376.816  Millions
Omega Therapeutics Inc   3.80 $ 101.898  Millions$ 26.816  Millions
Miromatrix Medical inc   3.46 $ 17.192  Millions$ 4.966  Millions
Eiger Biopharmaceuticals Inc   3.35 $ 54.624  Millions$ 16.319  Millions
Aligos Therapeutics Inc   3.32 $ 74.643  Millions$ 22.468  Millions
Gamida Cell Ltd   3.32 $ 68.509  Millions$ 20.654  Millions
Poseida Therapeutics Inc   3.28 $ 252.664  Millions$ 76.973  Millions
Qiagen N v   3.20 $ 2,147.560  Millions$ 672.125  Millions
Inmune Bio Inc   3.18 $ 45.611  Millions$ 14.356  Millions
Orchard Therapeutics Plc  3.12 $ 153.923  Millions$ 49.375  Millions
Sangamo Therapeutics Inc   3.04 $ 147.576  Millions$ 48.482  Millions
Precision Biosciences Inc  2.99 $ 151.162  Millions$ 50.617  Millions
Xtant Medical Holdings Inc   2.92 $ 64.107  Millions$ 21.921  Millions
Adaptimmune Therapeutics Plc  2.92 $ 219.368  Millions$ 75.146  Millions
Regenxbio Inc   2.87 $ 365.838  Millions$ 127.346  Millions
Amgen Inc   2.86 $ 48,477.000  Millions$ 16,954.000  Millions
Arcellx Inc   2.84 $ 491.456  Millions$ 173.149  Millions
Lineage Cell Therapeutics Inc   2.74 $ 43.481  Millions$ 15.881  Millions
Nanostring Technologies Inc   2.73 $ 211.807  Millions$ 77.532  Millions
Windtree Therapeutics Inc  2.72 $ 8.908  Millions$ 3.270  Millions
Repligen Corp  2.72 $ 978.456  Millions$ 360.049  Millions
Seagen Inc   2.67 $ 2,551.593  Millions$ 954.716  Millions
Coeptis Therapeutics Holdings Inc   2.57 $ 4.120  Millions$ 1.605  Millions
Moderna Inc   2.46 $ 10,799.000  Millions$ 4,385.000  Millions
Neurocrine Biosciences Inc   2.39 $ 1,649.900  Millions$ 691.600  Millions
Immunitybio inc   2.38 $ 215.082  Millions$ 90.324  Millions
Champions Oncology Inc   2.09 $ 14.017  Millions$ 6.707  Millions
Biomx Inc   1.98 $ 25.301  Millions$ 12.784  Millions

Date modified: 2023-11-01T19:14:13+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com